SAM SIMON: Open Payments
NPI 1326769399 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$680 in 30 payments from 6 companies in 2025. Trend: 2023 $331 · 2024 $588 · 2025 $680
Food & beverage: $680
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 9 | $255 |
| ABBVIE INC. | 8 | $140 |
| E.R. Squibb & Sons, L.L.C. | 4 | $107 |
| Otsuka America Pharmaceutical, Inc. | 5 | $98 |
| Teva Pharmaceuticals USA, Inc. | 2 | $47 |
| Almatica Pharma LLC | 2 | $33 |
Products named: INGREZZA, VRAYLAR, COBENFY, REXULTI, UZEDY, LOREEV XR, ABILIFY MAINTENA.
Industry payments across PA — which companies pay providers there.
